Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Katelyn T. Byrne(Portland State University), Robert H. Vonderheide(University of Pennsylvania)
Cited by 178
Related Papers
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
|Cancer Immunology Research|2015|467
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>
|Journal of Clinical Oncology|2021|238
Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19
|Science Immunology|2021|206
Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
|The Journal of Experimental Medicine|2020|175